Moderna, Inc.: Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years

Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children

Related Keywords

Australia ,Taiwan ,Cambridge ,Cambridgeshire ,United Kingdom ,New Zealand ,Canada ,Israel ,Argentina ,Australian ,Australians ,Lavina Talukdar ,Michael Azrak ,Luke Mircea Willats ,Us Department Of Health ,Human Services ,National Institutes Of Health ,Biomedical Advanced Research ,National Institute Of Allergy ,Australian Technical Advisory Group On Immunisation ,Development Authority ,Media Relations Communications ,Nasdaq ,Exchange Commission ,Moderna Inc ,Office Of The ,Therapeutic Goods Administration ,General Manager ,National Institute ,Infectious Diseases ,National Institutes ,Assistant Secretary ,Australian Government ,Australian Technical Advisory Group ,Goods Administration ,Private Securities Litigation Reform Act ,Annual Report ,Media Relations ,Vice President ,Moderna ,Herapeutic ,Foods ,Administration ,Migrants ,Provisional ,Approval ,Covid ,Vaccine ,Children ,Ged ,Months ,Five ,Tears ,